Variation within DNA repair pathway genes and risk of multiple sclerosis

American Journal of Epidemiology

Volumn 172, Issue 2, 2010, Pages 217-224

  Briggs, Farren B S ^a   Goldstein, Benjamin A ^a   McCauley, Jacob L ^b   Zuvich, Rebecca L ^c   De Jager, Philip L ^d,e   Rioux, John D ^f   Ivinson, Adrian J ^g   Compston, Alastair ^h   Hafler, David A ⁱ   Hauser, Stephen L ^j   Oksenberg, Jorge R ^j   Sawcer, Stephen J ^h   Pericak Vance, Margaret A ^b   Haines, Jonathan L ^c,e   Barcellos, Lisa F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^f MONTREAL HEART INSTITUTE   (Canada)

^g The Harvard Center for Neurodegeneration & Repair   (United States)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁱ YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

decision trees; DNA repair; epistasis, genetic; genetic variation; multiple sclerosis

Indexed keywords

HLA DR ANTIGEN;

ANTIGEN; DISEASE INCIDENCE; EPISTASIS; GENE EXPRESSION; GENETIC VARIATION; GENOTYPE; NERVOUS SYSTEM; PEPTIDE; POLYMORPHISM; REGRESSION ANALYSIS; RISK FACTOR;

ARTICLE; CHROMOSOME 6P; CONTROLLED STUDY; DNA REPAIR; DOUBLE STRANDED DNA BREAK; EXCISION REPAIR; GENE; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION; GENETIC EPISTASIS; GENETIC RISK; GENETIC SCREENING; GENETIC TRANSCRIPTION; GENOTYPE; GTF2H4 GENE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NONHOMOLOGOUS END JOINING; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

EUROPE;

EID: 77955005160     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwq086     Document Type: Article

References (54)

1. Oksenberg JR, Barcellos LF. Multiple sclerosis genetics: leaving no stone unturned. Genes Immun. 2005;6(5):375-387.
2. Oksenberg JR, Barcellos LF, Cree BA, et al. Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Am J Hum Genet. 2004;74(1):160-167.
3. Caillier SJ, Briggs F, Cree BA, et al. Uncoupling the roles of HLA-DRB1 and HLA-DRB5 genes in multiple sclerosis. J Immunol. 2008;181(8):5473-5480.
4. Hafler DA, Compston A, Sawcer S, et al. Risk alleles for multiple sclerosis identified by a genomewide study. International Multiple Sclerosis Genetics Consortium. N Engl J Med. 2007;357(9):851-862.
5. International Multiple Sclerosis Genetics Consortium (IMSGC). Refining genetic associations in multiple sclerosis. Lancet Neurol. 2008;7(7):567-569.
6. Rubio JP, Stankovich J, Field J, et al. Replication of KIAA0350, IL2RA, RPL5 and CD58 as multiple sclerosis susceptibility genes in Australians. Genes Immun. 2008; 9(7):624-630.
7. Perera D, Stankovich J, Butzkueven H, et al. Fine mapping of multiple sclerosis susceptibility genes provides evidence of allelic heterogeneity at the IL2RA locus. J Neuroimmunol. 2009;211(1-2):105-109.
8. De Jager PL, Baecher-Allan C, Maier LM, et al. The role of the CD58 locus in multiple sclerosis. Proc Natl Acad Sci USA. 2009;106(13):5264-5269.
9. De Jager PL, Jia X, Wang J, et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet. 2009; 41(7):776-782.
10. International Multiple Sclerosis Genetics Consortium (IMSGC). Comprehensive follow-up of the first genome-wide association study of multiple sclerosis identifies KIF21B and TMEM39A as susceptibility loci. Hum Mol Genet. 2010; 19(5):953-962.
11. Altshuler D, Daly MJ, Lander ES. Genetic mapping in human disease. Science. 2008;322(5903):881-888.
12. Thomas DC. The need for a systematic approach to complex pathways in molecular epidemiology. Cancer Epidemiol Bio-markers Prev. 2005;14(3):557-559.
13. Baranzini SE, Galwey NW, Wang J, et al. Pathway and network-based analysis of genome-wide association studies in multiple sclerosis. Hum Mol Genet. 2009;18(11):2078-2090.
14. Vladimirova O, O'Connor J, Cahill A, et al. Oxidative damage to DNA in plaques of MS brains. Mult Scler. 1998;4(5): 413-418.
15. Lu F, Selak M, O'Connor J, et al. Oxidative damage to mito-chondrial DNA and activity of mitochondrial enzymes in chronic active lesions of multiple sclerosis. J Neurol Sci. 2000; 177(2):95-103.
16. Tajouri L, Mellick AS, Ashton KJ, et al. Quantitative and qualitative changes in gene expression patterns characterize the activity of plaques in multiple sclerosis. Brain Res Mol Brain Res. 2003;119(2):170-183.
17. Mandel M, Gurevich M, Pauzner R, et al. Autoimmunity gene expression portrait: specific signature that intersects or differentiates between multiple sclerosis and systemic lupus erythematosus. Clin Exp Immunol. 2004;138(1):164-170.
18. Satoh J, Nakanishi M, Koike F, et al. Microarray analysis identifies an aberrant expression of apoptosis and DNA damage-regulatory genes in multiple sclerosis. Neurobiol Dis. 2005;18(3):537-550.
19. Giovannoni G, Heales SJ, Land JM, et al. The potential role of nitric oxide in multiple sclerosis. Mult Scler. 1998;4(3): 212-216.
20. Hernán MA, Olek MJ, Ascherio A. Cigarette smoking and incidence of multiple sclerosis. Am J Epidemiol. 2001;154(1): 69-74.
21. Riise T, Nortvedt MW, Ascherio A. Smoking is a risk factor for multiple sclerosis. Neurology. 2003;61(8):1122-1124.
22. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50(1):121-127.
23. Thompson AJ, Montalban X, Barkhof F, et al. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol. 2000;47(6):831-835. (Pubitemid 30390209)
24. Wood RD, Mitchell M, Lindahl T. Human DNA repair genes, 2005. Mutat Res. 2005;577(1-2):275-283.
25. Song CM, Yeo BH, Tantoso E, et al. iHAP-integrated hap-lotype analysis pipeline for characterizing the haplotype structure of genes [published online December 1, 2006]. BMC Bioinformatics. 2006;7:525. (doi:10.1186/1471-2105-7-525) . (Pubitemid 44941822)
26. International HapMap Consortium. The International HapMap Project. Nature. 2003;426(6968):789-796.
27. Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res. 2003;31(13): 3812-3814.
28. Steemers FJ, Chang W, Lee G, et al. Whole-genome geno-typing with the single-base extension assay. Nat Methods. 2006;3(1):31-33.
29. de Bakker PI, McVean G, Sabeti PC, et al. A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC. Nat Genet. 2006;38(10): 1166-1172.
30. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81(3):559-575.
31. Gabriel SB, Schaffner SF, Nguyen H, et al. The structure of haplotype blocks in the human genome. Science. 2002; 296(5576):2225-2229.
32. Barrett JC, Fry B, Maller J, et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21(2):263-265.
33. Valdes AM, Thomson G. Detecting disease-predisposing variants: the haplotype method. Am J Hum Genet. 1997;60(3): 703-716.
34. Wu X, Gu J, Grossman HB, et al. Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet. 2006;78(3):464-479.
35. Beuten J, Gelfond JA, Franke JL, et al. Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2009;18(6):1869-1880.
36. Cuzick JA. Wilcoxon-type test for trend. Stat Med. 1985;4(1): 87-90.
37. Breiman L. Random forests. Mach Learn. 2001;45(1):5-32.
38. Browning SR, Browning BL. Rapid and accurate haplotype phasing and missing-data inference for whole-genome association studies by use of localized haplotype clustering. Am J Hum Genet. 2007;81(5):1084-1097.
39. Rivera-Munoz P, Malivert L, Derdouch S, et al. DNA repair and the immune system: from V(D)J recombination to aging lymphocytes. Eur J Immunol. 2007;37(suppl 1):S71-S82.
40. Fishel ML, Vasko MR, Kelley MR. DNA repair in neurons: so if they don't divide what's to repair? Mutat Res. 2007; 614(1-2):24-36.
41. Nouspikel T. DNA repair in mammalian cells: nucleotide excision repair: variations on versatility. Cell Mol Life Sci. 2009;66(6):994-1009.
42. Larsen NB, Rasmussen M, Rasmussen LJ. Nuclear and mito-chondrial DNA repair: similar pathways? Mitochondrion. 2005;5(2):89-108.
43. Yeo TW, De Jager PL, Gregory SG, et al. A second major histocompatibility complex susceptibility locus for multiple sclerosis. Ann Neurol. 2007;61(3):228-236.
44. Barcellos LF, Sawcer S, Ramsay PP, et al. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet. 2006;15(18):2813-2824.
45. Dyment DA, Herrera BM, Cader MZ, et al. Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance. Hum Mol Genet. 2005;14(14): 2019-2026.
46. Jones IM, Thomas CB, Xi T, et al. Exploration of methods to identify polymorphisms associated with variation in DNA repair capacity phenotypes. Mutat Res. 2007;616(1-2):213-220.
47. Shin A, Lee KM, Ahn B, et al. Genotype-phenotype relationship between DNA repair gene genetic polymorphisms and DNA repair capacity. Asian Pac J Cancer Prev. 2008;9(3): 501-505.
48. Norbury CJ, Zhivotovsky B. DNA damage-induced apoptosis. Oncogene. 2004;23(16):2797-2808.
49. d'Adda di Fagagna F. Living on a break: cellular senescence as a DNA-damage response. Nat Rev Cancer. 2008;8(7): 512-522.
50. Horikawa Y, Gu J, Wu X. Genetic susceptibility to bladder cancer withan emphasis on gene-gene and gene-environmental interactions. Curr Opin Urol. 2008;18(5):493-498.
51. Taioli E. Gene-environment interaction in tobacco-related cancers. Carcinogenesis. 2008;29(8):1467-1474.
52. Nortvedt MW, Riise T, Maeland JG. Multiple sclerosis and lifestyle factors: the Hordaland Health Study. Neurol Sci. 2005;26(5):334-339.
53. Sundström P, Nyström L, Hallmans G. Smoke exposure increases the risk for multiple sclerosis. Eur J Neurol. 2008; 15(6):579-583.
54. Di Pauli F, Reindl M, Ehling R, et al. Smoking is a risk factor for early conversion to clinically definite multiple sclerosis. Mult Scler. 2008;14(8):1026-1030.